Impact of immunophenotyping on management of acute leukemias

Haematologica

Volumn 84, Issue 11, 1999, Pages 1024-1034

  Béné, Marie C ^a   Bernier, Michel ^b   Castoldi, Gianluigi ^c   Faure, Gilbert C ^a   Knapp, Walter ^d   Ludwig, Wolf D ^e   Matutes, Estella ^f   Orfao, Alberto ^g   Van't Veer, Mars ^h  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b JULES BORDET INSTITUTE   (Belgium)

^c S ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF VIENNA   (Austria)

^e Section of Pathology   (Germany)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute leukemia; Immunophenotyping; Minimal residual disease; Outcome

Indexed keywords

ACUTE LEUKEMIA; ARTICLE; BLAST CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PROGNOSIS;

ACUTE DISEASE; DISEASE MANAGEMENT; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE;

EID: 0344771685     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Zutter MM, Hess JL. Guidelines for the diagnosis of leukemia or lymphoma in children. Am J Clin Pathol 1998; 109 Suppl 1:S9-S22.
2. Taylor CG, Stasi R, Bastianelli C, et al. Diagnosis and classification of the acute leukaemias: recent advances and controversial issues. Hematopathol Mol Hematol 1996; 10:1-38.
3. Elghetany MT, MacCallum JM, Davey FR. The use of cytochemical procedures in the diagnosis and management of acute and chronic myeloid leukaemia. Clin Lab Med 1990;10:707-20.
4. Look AT. Oncogenic transcription factors in the human acute leukaemias. Science 1997; 278:1059-64.
5. Foon KA, Tood RF. Immunologic classification of leukaemia and lymphoma. Blood 1986; 68:1-31.
6. Béné MC, Castoldi GL, Knapp W, et al (on behalf of EGIL). Proposals for the immunological classification of leukaemias. Leukemia 1995; 9:1783-6.
7. Stewart CC, Behm FG, Carey JL, et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry 1998; 30:231-5.
8. Casasnovas RO, Campos L, Mugneret F, et al. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukaemia subtypes: a prospective study of 432 patients. Leukemia 1998; 12:34-43.
9. Lenormand B, Béné MC, Lesesve JF, et al. PreB1 (CD10-) acute lymphoblastic leukaemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe d'Etude Immunologique des Leucémies. Leuk Lymphoma 1998; 28:329-42.
10. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukaemia: a curable disease. Leukemia 1998; 12:1866-80.
11. Kluin-Nelemans JC, van Wering ER, van 'T Veer MB, et al. Pitfalls in the immunophenotyping of leukaemia and leukaemic lymphomas: survey of 9 years of quality control in The Netherlands. Dutch Cooperative Study Group on Immunophenotyping of Haematological Malignancies (SIHON). Br J Haematol 1996; 95:692-9.
12. Knapp W, Majdic O, Strobl H. Flow cytometric analysis of intracellular myeloperoxidase and lactoferrin in leukaemia diagnosis. Rec Res Cancer Res 1993; 131: 31-40.
13. Stasi R, Del Poeta G, Venditti A, et al. Lineage identification of acute leukaemias: relevance of immunologic and ultrastructural techniques. Hematol Pathol 1995; 9:79-94.
14. Konikova E, Glasova M, Kusenda J, Babusikova O. Intracellular markers in acute myeloid leukaemia diagnosis. Neoplasma 1998; 45:282-91.
15. Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 1996; 10:1383-9.
16. Lanza F, Latoracca A, Moretti S, Castagnari B, Ferrari L, Castoldi G. Comparative analysis of different permeabilization methods for the flow cytometric measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukaemic cells. Cytometry 1997; 30:134-44.
17. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukaemia by flow cytometric analysis. Use of CD45 and right angle light scatter to gate on leukaemic blasts in three-color analysis. Am J Clin Pathol 1993; 100:534-40.
18. Drexler HG, Thiel E, Ludwig WD. Acute myeloid leukaemias expressing lymphoid associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7:489-98.
19. Lenkei R, Gratama JW, Rothe G, et al. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry 1998; 33:188-96.
20. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med1998; 339:605-15.
21. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children, with acute lymphoblastic leukaemia. J Clin Oncol 1996; 14:18-24.
22. Crump M, Keating A. Acute leukaemia in adults. Curr Opin Hematol 1995; 2:247-54.
23. Bernier M, Massy M, Deleeuw N, Bron N, Debusscher L, Stryckmans P. Immunological definition of acute minimally differentiated myeloid leukaemia (MO) and acute undifferentiated leukaemia (AUL). Leuk Lymphoma 1995; 18(Suppl.1):13-7.
24. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukaemia. Blood 1998; 91:735-46.
25. Garand R, Béné MC. Incidence, clinical and laboratory features, and prognostic significance of immunophenotypic subgroups in acute lymphoblastic leukaemia: the GEIL experience. Rec Res Cancer Res 1993; 131: 283-95.
26. Garand R, Voisin S, Papin S, et al. Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucémies. Leukemia 1993; 7:161-7.
27. Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukaemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Acute Lymphoblastic Leukaemia. Blood 1994; 84:1603-12.
28. Reiter A, Schrappe M, Ludwig WD, et al. Favourable outcome of B-cell acute lymphoblastic leukaemia in childhood: a report of the three consecutive studies of the BFM group. Blood 1996; 80:2471-8.
29. LeredeT, Bassab R, Rossi A, et al. Therapeutic impact of adult-type lymphoblastic leukaemia regimens in B-cell/L3 acute leukaemia and advanced stage Burkitt's lymphoma. Haematologica 1996; 81:442-9.
30. Chen CS, Sorensen PHB, Domer PH, et al. Molecular rearrangements on chromosome 11 q23 predominate in infant acute lymphoblastic leukaemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81:2386-93.
31. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics and treatment outcome of adult pro-B acute lymphoblastic leukaemia : results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 6:1898-909.
32. Pui CH. Acute lymphoblastic leukaemia. Ped Clin N Am 1997; 44:831-46.
33. Crist W, Boyett J, Jackson J, et al. Prognostic importance of pre-B cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukaemia: a Pediatric Oncology Group study. Blood 1989; 74:1252-9.
34. Stevens RF. Acute myeloblastic leukaemia. Br Med Bull 1996; 52:764-77.
35. Lowenberg B. Treatment of the elderly patient with acute myeloid leukaemia. Baillière's Clin Haematol 1996; 9:147-59.
36. Degos L. Differentiation therapy in acute promyelocytic leukaemia: European experience. J Cell Physiol 1997; 173:285-7.
37. Solary E, Casasnovas RO, Campos L, et al. Surface markers in adult acute myeloblastic leukaemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). Leukemia 1992; 6:393-9.
38. Fergedal M, Astrom M, Tidefelt U, Karlsson MG. Differences in CD14 and alpha naphthyl acetate esterase positivity and relation to prognosis in AML. Leuk Res 1998; 22:25-30.
39. Warrel RPJr, De Thé H, Wang ZY, Degos L. Acute promyelocytic leukaemia. N Engl J Med 1993; 329: 177-89.
40. Garand R, Béné MC. A new approach of acute lymphoblastic leukaemia immunophenotypic classification: 1984-1994 the GEIL experience. Groupe d'Etude Immunologique des Leucémies. Leuk Lymphoma 1994; 13 (Suppl 1):1-5.
41. Philip PJ, Monpoux F, Sudaka I, et al. Multiphenotypic acute leukaemias: clinicopathologic correlations and response to therapy. Leuk Lymphoma 1992; 7: 489-95.
42. Wiersma S, Onega J, Sobel E, Weinberg K. Clinical importance of myeloid antigens expression in acute lymphoblastic leukaemia in childhood. N Engl J Med 1991; 324:800-8.
43. Fink FM, Kol̈ler U, Mayer H, et al. Myeloid-associated antigen expression in childhood acute lymphoblastic leukaemia. Rec Res Cancer Res 1993; 131:66-75.
44. Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic significance in children treated for acute lymphoblastic leukaemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92:795-801.
45. Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukaemia, J Clin Oncol 1998; 16:3768-73.
46. Borowitz MJ, RubnitzJ, Nash M, Pullen DJ, Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 1998; 12: 1764-70.
47. Baruchel A, CayuelaJM, Ballerini P, et al. The majority of myeloid antigen positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol 1997; 99: 101-6.
48. Matutes E, Morilla R, Harahat N, et al. Definition of acute biphenotypic leukaemia. Haematologica 1997; 82:64-6.
49. EGIL. The value of c-kit in the diagnosis of biphenotypic acute leukaemia. Leukaemia 1998; 12:2038.
50. Rigolin GM, Lanza F, Castoldi G. Photomultipliervoltage setting: possible important source ofvariability in molecular equivalents of soluble fluorochrome (MESF) calculation? Cytometry 1995; 20:362-8.
51. Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression of N-CAM (CD56) on acute leukaemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma 1995; 19:295-300.
52. Paietta E, Andersen J, Yunis J, et al. Acute myeloid leukaemia expressing the leucocyte integrin CD11b -a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol 1998; 100:265-72.
53. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwanz JF, SjaperJH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined bya monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133:157-65.
54. Borowitz MJ, Shuster JJ, Civin CI, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukaemia: a Pediatric Oncology Group study. J Clin Oncol 1990; 8:1389-98.
55. Sperling C, BüchnerT, Creutzig U, et al. Clinical, morphological, cytogenetic and prognostic implications of CD34 expression in childhood and adults de novo AML. Leuk Lymphoma 1995; 17:417-26.
56. Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukaemia. Blood 1993 1; 82:889-94.
57. Vanhaecke D, Béné MC, Garand R, Faure GC. Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukaemia. Leuk Lymphoma 1995; 20:137-42.
58. Cascavilla N, Musto P, D'Arena G, Ladogana S, Matera R, Carotenuto M. Adult and childhood acute lymphoblastic leukaemia: clinico-biological differences based on CD34 antigen expression. Haematologica 1997; 82:31-7.
59. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi GL. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukaemia. Leuk Lymphoma 1994; 13(Suppl 1):81-5.
60. Raspadori D, Lauria F, Ventura MA, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukaemia: analysis of 141 cases. Leuk Res 1997; 21:603-7.
61. Steen R, Tjonnfjord GE, Gaudernack G, Brinch L, Egeland T. Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. Br J Haematol 1996; 94:597-605.
62. Lanza F, Moretti S, Castagnari B, et al. CD34+ leukaemic cells assessed by different CD34 monoclonal antibodies. Leuk Lymphoma 1995; 18 (Suppl 1):25-30.
63. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989; 7:339-69.
64. Behm FG, Raimondi SC, Schell MJ, Look TL, Rivera GK, Pui CH. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukaemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood 1992; 4:1011-6.
65. Ratei R, Sperling C, Karawajew L, et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukaemia. Ann Hematol 1998; 77:107-14.
66. Lagaudriere-Gesbert C, Le Naour F, Lebel-Binay S, et al. Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGFactivity. Cell Immunol 1997; 182: 105-12.
67. Mandelli F, Petti MC, Lo Coco F. Therapy of acute myeloid leukaemia: towards a patient-oriented, risk-adapted approach. Haematologica 1998; 83:1015-23.
68. San Miguel JF, Ojeda E, Gonzalez M, et al. Prognostic value of immunological markers in acute myeloblastic leukaemia. Leukemia 1989; 3:108-11.
69. Uckun FM, Steinherz G, Sather H, et al. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a children's cancer group study. Blood 1996; 88:4288-95.
70. Vidriales MB, Orfao A, Lopez-Berges MC, et al. Prognostic value of S-phase cells in AML patients. Br J Haematol 1995; 89:342-8.
71. Berg EL, Goldstein LA, Jutila MA, et al. Homing receptors, and vascular addressins: cell adhesion molecules that direct lymphocyte traffic, Immunol Rev 1989; 108:5-18.
72. Khaldoyanidi S, Achtnich M, Hehlmann R, Zöller M. Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukaemia: inverse correlation between expression and tumor progression. Leuk Res 1996; 10:839-51.
73. Legras S, Gunthert V, Stauder R, et al. A strong expression of CD44-6v correlated with shorter survival of patients with acute myeloblastic leukaemia. Blood 1998; 91:3401-13.
74. Mann KP, De Castro CM, Liu J, Moore JO, Bigner SH, Traweek T. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukaemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997; 107:653-60.
75. Vidriales MB, Orfao A, Gonzalez M, et al. Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukaemia. Leukemia 1993; 7: 2026-9.
76. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90:1643-8.
77. Scott AA, Head DR, Kopecky KJ, et al. HLA-DR-, CD33+, CD56+, CD16-myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukaemia M3. Blood 1994; 84:244-55.
78. Archimbaud E, Thomas X, Campos S, Magaud JP, Doré JF, Fiere D. Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukaemia: relationship with initial characteristics and prognosis. Leukemia 1992; 6:265-71.
79. Mielcarek M, Sperling C, Schrappe M, Meyer U, Riehm H, Ludwig WD. Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome. Br J Haematol 1997; 96:301-7.
80. Stoetzer OJ, Nüssler V, Darsow M, et al. Association of bcl-2, bax, bcl-xl and interleukin-1β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukaemia. Leukemia 1996; 10 (Suppl 3):S18-22.
81. Ijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of fas (CD95) in acute myeloid leukaemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood 1997; 90:4901-9.
82. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukaemia: a comparison of different diagnostic methods. Leukemia 1997; 11:1067-72.
83. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56:3010-20.
84. Marie JP, Legrand O, Perrot JY, Chevillard S, Huet S, Robert J. Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. Semin Hematol 1997; 34(S5):63-71.
85. Nussler V, Pelka-Fleischer R, Zwierzina H, et al. P-glycoprotein expression in patients with acute leukaemia-clinical relevance. Leukemia 1996; 10:S23-S31.
86. Ludescher C, EistererW, Hilbe W, et al.Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukaemia compared to acute myeloid leukaemia. Leukemia 1995; 2:350-6.
87. Zochbauer S, Gsur A, Brunner R, Kyrie PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukaemia. Leukemia 1994; 8:974-7.
88. Senent L, Jarque I, Martin G, et al. P-glycoprotein expression and prognostic value in acute myeloid leukaemia. Haematologica 1998; 83:783-7.
89. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083-91.
90. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukaemia cells at diagnosis. Blood 1992; 79:473-6.
91. Martinez A, SanMiguel JF, Valverde B, et al. Functional expression of MDR-1 in acute myeloid leukaemia: correlation with the clinical-biological immunophenotypical and prognostic disease characteristics. Ann Hematol 1997; 75:52-6.
92. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukaemia. Blood 1998; 91:2092-863.
93. Wattel E, Lepelley P, Merlat A, et al. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukaemia: absence of correlation with response to treatment. Leukemia 1995; 9:1870-4.
94. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukaemia: prognostic implications. Blood 1993; 81: 2394-8.
95. Volm M, Stammler G, Zintl F, Koomagi R, Sauerbrey A. Expression of lung-resistance related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukaemia. Anticancer Drugs 1997; 8:662-5.
96. Poncelet P, Carayon P. Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods 1985; 85:65-74.
97. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukaemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11:2075-8.
98. Taskov H, Pashov A, Dimitrova E, Yordanova M, Serbinova M. Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukaemia. Leuk Res 1996; 20:75-9.
99. Borowitz MJ, ShusterJ, Caroll A, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukaemia. A pediatric oncology group study. Blood 1997; 89:3960-6.
100. Baer MR. Assessment of minimal residual disease in patients with acute leukaemia. Curr Opin Oncol 1998; 10:17-22.
101. Orfao A, Ciudad J, Lopez-Berges MC, et al. Acute lymphoblastic leukaemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994; 13 (Suppl1):87-90.
102. Brisco MJ, Hughes E, Neoh SH, et al. Relationship between minimal residual disease and outcome in acute lymphoblastic leukaemia. Blood 1996; 87: 5251-6.
103. Lucio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-27.
104. San Miguel JF, Martinez A, Macedo MB, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukaemia patients. Blood 1997; 90: 2465-70.
105. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550-4.
106. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukaemia. J Clin Oncol 1998; 16:3774-81.
107. Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998; 101:158-64.
108. Engel H, Goodacre A, Keyhani A, et al. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 1997; 99:64-75.
109. Roth MS, Terry VH. Application of the polymerase chain reaction for detection of minimal residual disease of hematologic malignancies. Henry Ford Hosp Med J 1991; 39:112-6.
110. Morgan GJ, Pratt G. Modern molecular diagnostics and the management of haematological malignancies. Clin Lab Haematol 1998; 20:135-41.